Is uniQure's gene therapy worth $1.4M?

German cost-effectiveness watchdogs aren't among pharma's favorite people. Since lawmakers instituted a tough price-setting process, state officials have questioned the benefits of one new drug after another--to the point where some drugmakers decided not to launch there at all. But a debate now playing out there is different. The first of its kind, actually; the Federal Joint Committee is assessing uniQure's ($QURE) Glybera, the first-ever gene therapy approved in Europe, and now the world's most expensive drug at €1.1 million ($1.4 million). And the questions raised in Germany offer a preview of reimbursement conversations in other countries, about this and other uber-pricey gene therapies. More from FiercePharma